Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

This study tests a drug called verteporfin (commonly used in eye treatments) as a potential treatment for recurrent high-grade brain cancer (glioblastoma) in patients whose tumors have a mutation or amplification of a gene called EGFR, which may make the cancer sensitive to this drug. **You may be eligible if...** - You have recurrent or progressive grade 4 glioblastoma - Your tumor has an EGFR mutation or amplification (determined by standard testing) - You have already received standard first-line treatment (radiation plus temozolomide chemotherapy) - Your MRI shows clear evidence of tumor growth or progression - You are willing to have a central venous access device placed for IV treatment **You may NOT be eligible if...** - Your imaging changes may be due to radiation damage rather than true tumor progression (you should receive bevacizumab first) - Your overall health status is too poor to tolerate treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.